Cytiva has partnered with biopharma CDMO Mycenax Biotech to expand commercial manufacturing of its first biosimilar
Cytiva, global life science specialist, has partnered with Mycenax Biotech, a biopharmaceutical CDMO company, to launch Taiwan's first continuous bioprocessing lab.
Built within Mycenax's Research Center, the new lab will enable the company to expand the commercial manufacturing for their first biosimilar project.
Pei-Jiun Chen, CEO of Mycenax, said: "We have been devoted to the development of continuous bioprocessing since 2017. We have a biosimilar project that adopted continuous bioprocessing technology and successfully entered Phase I clinical trial in European Union. This collaboration enables us to provide an innovative platform in the biopharmaceutical industry."
Yu Lihua, Cytiva Greater China General Manager, added: "According to the Global Biopharma Resilience Index, collaboration can remove the bottlenecks to development and innovation. By working together, Cytiva and Mycenax can expand the lab into a training and demo centre, empowering local talent development and bringing a boost to the biotechnology industry in Taiwan. Our companies are excited about this bright beginning."
In this new lab, Cytiva will provide its comprehensive product portfolio, including Xcellerex XDR single-use stirred-tank bioreactors, ReadyToProcess WAVE bioreactors, ÄKTA Protein Purification Systems, etc., to complete both the continuous process platform and the scale-up manufacturing platform. In addition, OptiRun, Cytiva's data-driven advisory services will further help Mycenax implement an integrated strategy to optimise its entire continuous bioprocess workflow.